Apellis Pharmaceuticals, Inc. (APLS)
Price:
21.79 USD
( + 0.36 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
BioNTech SE
VALUE SCORE:
6
2nd position
Atara Biotherapeutics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
11
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
No data to display
DESCRIPTION
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment of cold agglutinin disease (CAD), and hematopoietic stem cell transplantation-associated thrombotic microangiopathy (HSCT-TMA) in hematology; C3 glomerulopathy (C3G), and immune complex membranoproliferative glomerulonephritis (IC-MPGN) in nephrology; and amyotrophic lateral sclerosis (ALS) in neurology. In addition, the company develops APL-2006, a bispecific C3 and VEGF inhibitor for treating complement-mediated disorders; APL-1030, a C3 inhibitor for the treatment of multiple neurodegenerative diseases; and the combination of EMPAVELI and a small interfering RNA, or siRNA for reducing the production of C3 proteins by the liver. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) to co-develop pegcetacoplan; and a research collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is based in Waltham, Massachusetts.
NEWS
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
zacks.com
2026-02-25 09:56:20APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
zacks.com
2026-02-24 12:01:20Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago.
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2026-02-24 12:01:19While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-24 11:48:08Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-24 07:05:00WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
2026-02-23 07:00:00WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday
defenseworld.net
2026-02-22 03:26:57Apellis Pharmaceuticals (NASDAQ: APLS - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
globenewswire.com
2026-02-19 07:00:00Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Hold” from Analysts
defenseworld.net
2026-02-19 01:56:50Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have been given an average rating of "Hold" by the twenty-one analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and twelve have given a buy recommendation to
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
zacks.com
2026-02-17 11:02:06Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-10 07:00:00WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET.
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
zacks.com
2026-02-03 11:02:06Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
zacks.com
2026-01-29 08:06:16Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
prnewswire.com
2026-01-27 18:02:00NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions.
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $60,890.69 in Stock
defenseworld.net
2026-01-26 05:22:47Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Caroline Baumal sold 2,797 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $60,890.69. Following the completion of the transaction, the insider directly owned 86,527 shares of the company's
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $73,386.67 in Stock
defenseworld.net
2026-01-26 05:22:45Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $73,386.67. Following the sale, the insider owned 78,353 shares of the company's stock, valued
No data to display
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
zacks.com
2026-02-25 09:56:20APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
zacks.com
2026-02-24 12:01:20Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a year ago.
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
zacks.com
2026-02-24 12:01:19While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-24 11:48:08Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-24 07:05:00WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
globenewswire.com
2026-02-23 07:00:00WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, at 9:50 a.m. ET.
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday
defenseworld.net
2026-02-22 03:26:57Apellis Pharmaceuticals (NASDAQ: APLS - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to post earnings of ($0.41) per share and revenue of $199.2760 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for
Apellis Announces Eight Oral Presentations at the 49th Macula Society Annual Meeting
globenewswire.com
2026-02-19 07:00:00Company will debut five-year results from GALE study showing meaningful impact of early and continuous treatment with SYFOVRE ® (pegcetacoplan injection) WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49th Macula Society Annual Meeting, taking place February 25-28 in San Diego, California.
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Recommendation of “Hold” from Analysts
defenseworld.net
2026-02-19 01:56:50Shares of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) have been given an average rating of "Hold" by the twenty-one analysts that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and twelve have given a buy recommendation to
Earnings Preview: Apellis Pharmaceuticals, Inc. (APLS) Q4 Earnings Expected to Decline
zacks.com
2026-02-17 11:02:06Apellis Pharmaceuticals (APLS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis Pharmaceuticals to Host Conference Call on February 24, 2026, to Discuss Fourth Quarter and Full Year 2025 Financial Results
globenewswire.com
2026-02-10 07:00:00WALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026 at 8:30 a.m. ET.
5 Drug/Biotech Stocks Likely to Outperform Q4 Earnings Estimates
zacks.com
2026-02-03 11:02:06Let us look at some drug/biotech stocks, ZTS, PCRX, APLS, ACAD and DNLI, which are poised to beat on fourth-quarter 2025 earnings.
Apellis Pharmaceuticals (APLS) Surges 5.8%: Is This an Indication of Further Gains?
zacks.com
2026-01-29 08:06:16Apellis Pharmaceuticals (APLS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
prnewswire.com
2026-01-27 18:02:00NEW YORK, Jan. 27, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400, S&P SmallCap 600: S&P SmallCap 600 constituent TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent SM Energy Co. (NYSE: SM) is acquiring Civitas Resources in a deal expected to be completed soon, pending final closing conditions.
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $60,890.69 in Stock
defenseworld.net
2026-01-26 05:22:47Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Caroline Baumal sold 2,797 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $60,890.69. Following the completion of the transaction, the insider directly owned 86,527 shares of the company's
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) Insider Sells $73,386.67 in Stock
defenseworld.net
2026-01-26 05:22:45Apellis Pharmaceuticals, Inc. (NASDAQ: APLS - Get Free Report) insider Mark Jeffrey Delong sold 3,371 shares of Apellis Pharmaceuticals stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $21.77, for a total value of $73,386.67. Following the sale, the insider owned 78,353 shares of the company's stock, valued